



Healthcare Private Equity

DLA Piper offers deep knowledge and experience to private equity (PE) businesses investing in healthcare companies. We deliver tailored, cost-effective legal solutions backed by industry insight and global reach.

Key differentiators



Healthcare insights. Our team brings extensive healthcare knowledge and experience, addressing complex challenges across the healthcare sector. We provide efficient, actionable guidance for your investments.



Government relations experience. Led by former United States Senator **Richard Burr (Washington, DC)**, DLA Piper Principal Policy Advisor, and a nationally recognized government advocacy team, we provide key insights into state and federal legislative developments. Our relationships with policymakers enable businesses to anticipate policy changes and develop bespoke advocacy strategies.



Experienced regulatory diligence. Our due diligence process is respected across the representations and warranties insurance industry, empowering businesses to mitigate risk, negotiate terms, facilitate corrective actions, and close transactions with confidence. With experience in Stark Law, fraud and abuse laws, corporate practice of medicine and dentistry, HIPAA, FDA regulations, antitrust, and emerging technologies, we pinpoint core risks and deliver practical solutions.



Deal volume capacity. Our deep bench mobilizes teams quickly to manage high transaction volumes, streamlining workflow and reducing reliance on multiple outside firms – saving both time and resources.



Lifecycle representation. We support businesses at every stage of the investment lifecycle, from initial platform acquisition to growth through add-ons and exit, ensuring continuity and value.



Deep PE relationships. With extensive experience representing investors, providers, limited partners, co-investors, and entrepreneurs, we foster connections that enhance opportunities. Our strong relationships across the PE landscape facilitate smooth transactions while protecting interests.



Middle-market knowledge. Our leadership in middle-market transactions offers insights into investor goals, deal structures, and competitive landscapes, enabling us to deliver tailored guidance that reflects current market trends.



Dispute resolution. Our litigation and dispute resolution team manages claims brought by and against PE sponsors and their portfolio companies. Whether facing a federal or state investigation or a post-closing dispute, DLA Piper attorneys implement strategies aimed at protecting and recouping your investment.



Competitive rates with fee certainty. We provide a commitment to fee certainty and cost predictability without compromising quality.

DLA Piper has supported hundreds of healthcare PE transactions since COVID-19, including dental, physician practice management (PPM), behavioral health, AI/technology, infusion, veterinary, and pharmacy.

Industry-leading clients



Recent experience

Physician practice management

- Served as lead counsel for a behavioral health platform recapitalization
- Served as lead counsel for an ambulatory infusion platform through a series of add-on acquisitions, followed by a sale event culminating in the highest MOIC in the organization's history
- Designed a DSO joint venture for a dentist alignment strategy, culminating in a successful leveraged buyout
- Implemented value-based solutions for MCOs in primary care, cancer care, and other provider specialties
- Developed assessment of joint venture alternatives for a women's health platform, leveraging commercial payor strategies to align with other physician practices and PPMs

Government advocacy

- Led strategic advocacy efforts resulting in Governor Gavin Newsom's veto of AB 3129 and coordinated with OHCA to facilitate CHOW applications
- Designed state government affairs campaigns securing Medicaid reimbursement increases for the behavioral health portfolio
- Maintained key relationships with senior government leadership of the current presidential administration

Disputes resolution

- Investigated a false disability claim and successfully recovered over USD30 million in damages from the departing physician-founder
- Defended infusion and specialty pharmacy business model, resolving "bet the company" payor litigation and United States Department of Justice investigation
- Defeated qui tam allegations tied to the opioid crisis against a national mail-order pharmacy and resolved issues with the Mass AGO and DOJ

Healthcare regulatory

- Led corporate redesign of national PPM emerging from Chapter 11 to manage corporate practice of medicine, Stark Law, and anti-kickback risks
- Conducted buy-side due diligence and assisted seller's counsel in preparation of Stark Law voluntary self-disclosures in connection with multiple LBO closings
- Developed physician compensation and incentive plan models in cardiovascular, pain management, urology, women's health, and multi-specialty practices
- Prepared numerous portfolio companies for sale through sell-side due diligence with senior leadership

Recognized for excellence

#2 Most Active Firm in Healthcare Private Equity – *PitchBook 2025*

#1 Global Private Equity Deal Volume – *PitchBook 2025*

Leading Firm – Healthcare – *Chambers USA 2025*

Leading Firm – Healthcare Service Providers – *The Legal 500 US 2025*

Leading Firm – Mid-Market PE Buyouts – *Chambers USA 2025*

Leader – Best Firms for Cost Control – *BTI Consulting Group 2024*

DLA Piper helps navigate the complexities of healthcare PE investments while protecting and growing your portfolio.

dlapiper.com